GSK Settles Another Zantac Cancer Lawsuit in California
GSK Plc settled a US lawsuit set to start in California over the UK drugmaker’s blockbuster heartburn medication Zantac, the second such agreement this month.
The company said it had reached a confidential settlement with claimants listed as Boyd/Steenvoord, resolving a case that was due to begin trial in California state court on April 2.
Former Zantac users who have sued GSK and other companies claim the drug’s active ingredient, ranitidine, degraded and turned into a potential carcinogen called NDMA under some conditions. The companies deny these claims.
The settlement “reflects the company’s desire to avoid the distraction related to protracted litigation,” GSK said.
Top photo: Zantac pills.
Popular Today
- The Nation’s Insurance Laboratory: What Liability Trends in California Mean for the Rest of the Country
- Severe Convective Storms: Risk, Field Reality and the Path to Resilience
- The Big Data/AI ‘Revolution’ Is Driving Up Verdicts, Settlements as Plaintiffs Buy In
- The Adjuster Tenure Problem
Popular This Month